# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Abbott (NYSE:ABT) today announced that the Government of Quebec's Régie de l'assurance maladie du Québec (RAMQ) publish...
Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vi...
Jim Cramer recommends buying Blackstone Inc. (BX) due to its strong companies and expects Lowe's (LOW) stock to benefit fro...
Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $14...
Index futures trading indicates cautious optimism as traders anticipate a busy week, with a slew of earnings reports, the two-d...
This verdict is part of nearly 1,000 lawsuits filed against Abbott Labs, its British rival Reckitt Benckiser, or both, in U.S. ...